Clover Health Investments Corp. [NASDAQ: CLOV] stock went on an upward path that rose over 1.51% on Tuesday, amounting to a one-week price decrease of less than -6.05%. The company report on August 31, 2022 that Clover Health to Present at 2022 Wells Fargo Healthcare Conference on September 7, 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced that its CEO, Vivek Garipalli, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 9:10 a.m. Eastern Time.
A live webcast of the presentation will be accessible from Clover Health’s investor relations website at https://investors.cloverhealth.com/. An archived replay of the presentation will be available from the same website for 12 months following the live presentation.
Over the last 12 months, CLOV stock dropped by -75.06%. The one-year Clover Health Investments Corp. stock forecast points to a potential upside of 43.58. The average equity rating for CLOV stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $979.19 million, with 476.06 million shares outstanding and 337.00 million shares in the current float. Compared to the average trading volume of 6.84M shares, CLOV stock reached a trading volume of 6430600 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Clover Health Investments Corp. [CLOV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $3.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Clover Health Investments Corp. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 02, 2022. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on February 02, 2022, representing the official price target for Clover Health Investments Corp. stock. Previously, the target price had yet another raise to $3, while SVB Leerink analysts kept a Mkt Perform rating on CLOV stock. On January 10, 2022, analysts decreased their price target for CLOV shares from 9 to 3.50.
The Average True Range (ATR) for Clover Health Investments Corp. is set at 0.14, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 0.38. The Price to Book ratio for the last quarter was 2.24, with the Price to Cash per share for the same quarter was set at 1.08.
CLOV Stock Performance Analysis:
Clover Health Investments Corp. [CLOV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.05. With this latest performance, CLOV shares dropped by -29.12% in over the last four-week period, additionally sinking by -44.04% over the last 6 months – not to mention a drop of -75.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 29.26, with the RSI for the last a single of trading hit 23.08, and the three-weeks RSI is set at 34.52 for Clover Health Investments Corp. [CLOV]. The present Moving Average for the last 50 days of trading for this stock 2.7000, while it was recorded at 2.0400 for the last single week of trading, and 2.8400 for the last 200 days.
Insight into Clover Health Investments Corp. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Clover Health Investments Corp. [CLOV] shares currently have an operating margin of -37.11. Clover Health Investments Corp.’s Net Margin is presently recorded at -38.21.
Return on Equity for this stock declined to -88.46, with Return on Assets sitting at -65.05.
Clover Health Investments Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.20.
CLOV Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp. go to 19.10%.
Clover Health Investments Corp. [CLOV] Insider Position Details
There are presently around $248 million, or 32.60% of CLOV stock, in the hands of institutional investors. The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 32,095,012, which is approximately 23.028% of the company’s market cap and around 3.10% of the total institutional ownership; BLACKROCK INC., holding 24,435,025 shares of the stock with an approximate value of $49.36 million in CLOV stocks shares; and STATE STREET CORP, currently with $16.06 million in CLOV stock with ownership of nearly 311.373% of the company’s market capitalization.
Positions in Clover Health Investments Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 93 institutional holders increased their position in Clover Health Investments Corp. [NASDAQ:CLOV] by around 51,251,715 shares. Additionally, 67 investors decreased positions by around 27,253,042 shares, while 50 investors held positions by with 44,493,479 shares. The mentioned changes placed institutional holdings at 122,998,236 shares, according to the latest SEC report filing. CLOV stock had 39 new institutional investments in for a total of 5,305,066 shares, while 32 institutional investors sold positions of 4,230,887 shares during the same period.